The increasing complexity of cancer chemotherapy now requires that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy, and review various agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
LowJ.A., WedamS.B., LeeJ.J.. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol.2005; 23(12): 2726–2734.
2.
DenduluriN., LeeJ.J., WalsheJ.. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest New Drugs.2007; 25(1): 63–67.
3.
ThomasE., TaberneroJ., FornierM.. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol.2007; 25(23): 3399–3406.
4.
PerezE.A., LerzoG., PivotX.. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol.2007; 25(23): 3407–3414.
5.
RochéH., YelleL., CognettiF.. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol.2007; 25(23): 3415–3420.
6.
DenduluriN., LowJ.A., LeeJ.J.. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol.2007; 25(23): 3421–3427.
7.
GalskyM.D., SmallE.J., OhW.K.. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol.2005; 23(7): 1439–1446.
8.
HussainM., TangenC.M., LaraP.N.Jr. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapynaïve patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol.2005; 23(34): 8724–8729.
9.
AjaniJ.A., SafranH., BokemeyerC.. A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Invest New Drugs.2006; 24(5): 441–446.
10.
WhiteheadR.P., McCoyS., RivkinS.E.. A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. Invest New Drugs.2006; 24(6): 515–520.
11.
FeldmanD.R., KondaguntaG.V., GinsbergM.S.. Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. Invest New Drugs.2007; 25(5): 487–490.
12.
VansteenkisteJ., LaraP.N.Jr, Le ChevalierT.. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol.2007; 25(23): 3448–3455.
13.
DreicerR., LiS., ManolaJ.. Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group. Cancer.2007; 110(4): 759–763.
14.
AghajanianC., BurrisHA3rd, JonesS.. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol.2007; 25(9): 1082–1088.
15.
ZhuangS.H., AgrawalM., EdgerlyM.. A phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer.2005; 103(9): 1932–1938.
KantarjianH., GilesF., WunderleL.. Nilotinib in imatinib-resistant CML and philadelphia chromosome-positive all. N Engl J Med, 2006; 354(24): 2542–2551.
18.
KantarjianH.M., GilesF., GattermannN.. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood.2007; 110(10): 3540–3546.
19.
JabbourE., KantarjianH., GilesF.. Treatment with nilotinib for patients with chronic myeloid leukemia (CML) who failed prior therapy with imatinib and dasatinib. Proc Am Soc Hematol.2006 (abstract 2171). http://www.abstracts2view.com/hem4806/view.php?nu=HEM06L1_2534&terms=. Accessed November 1, 2007.
20.
JabbourE., CortesJ., GilesF.. Preliminary activity of nilotinib (AMN107), a novel selective potent oral Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP). Proc Am Soc Hematol.2006 (abstract 2172). http://www.abstracts2view.com/hem4806/view.php?nu=HEM06L1_2532&terms=. Accessed November 1, 2007.
21.
le CoutreP., BhallaK., GilesF.. A phase ii study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant and -intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP). Proc Am Soc Hematol.2006 (abstract 165). http://www.abstracts2view.com/hem4806/view.php?nu=HEM06L1_4683&terms=. Accessed November 1, 2007.
22.
HochhausA., OttmannO.G., LauberS.. A phase II study of nilotinib, a novel inhibitor of c-kit, PDGFR, and Bcr-Abl, administered to patients with systemic mastocytosis. Proc Am Soc Hematol.2006 (abstract 2703). http://www.abstracts2view.com/hem4806/view.php?nu=HEM06L1_4529&terms=. Accessed November 1, 2007.
23.
KantarjianH.M., GattermannN., HochhausA.. A phase II study of nilotinib a novel tyrosine kinase inhibitor administered to imatinib-resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP). Proc Am Soc Hematol.2006 (abstract 2169). http://www.abstracts2view.com/hem4806/view.php?nu=HEM06L1_5658&terms=. Accessed November 1, 007.
24.
GilesF., le CoutreP., BhallaK.. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who have also failed dasatinib therapy. Proc Am Soc Hematol.2006 (abstract 2170). http://www.abstracts2view.com/hem4806/view.php?nu=HEM06L1_5666&terms=. Accessed November 1, 2007.
25.
OttmannO., KantarjianH., LarsonR.. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL). Proc Am Soc Hematol.2006 (abstract 1862). http://www.abstracts2view.com/hem4806/view.php?nu=HEM06L1_5695&terms=. Accessed November 1, 2007.
26.
le CoutreP., HochhausA., HeimD.. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to patients with hypereosiniphilic syndrome (HES). Proc Am Soc Hematol.2006 (abstract 4912). http://www.abstracts2view.com/hem4806/view.php?nu=HEM06L1_4833&terms=. Accessed November 1, 2007.
